Scholarlink

Introduction <p>Remibrutinib, an oral, highly selective, Bruton’s tyrosine kinase (BTK) inhibitor, has shown efficacy and favorable safety in pivotal global phase&#xa0;3 studies in patients with chronic spontaneous urticaria (CSU). This 52-week safety study evaluated the effect of remibrutinib in Japanese patients with CSU.</p> Methods <p>BISCUIT, a phase&#xa0;3 (NCT05048342), open-label, single-arm study, investigated the safety and efficacy of remibrutinib 25&#xa0;mg twice-daily as an add-on medication in Japanese patients with CSU who remain symptomatic despite treatment with H<sub>1</sub>-antihistamines. The primary endpoint was the proportion of patients with ≥ 1 adverse events (AEs).</p> Results <p>Overall, 71 Japanese patients (mean age 43.5&#xa0;years) had a median remibrutinib exposure of 52.1&#xa0;weeks; 87.3% of patients reported ≥ 1 AE, and all events were mild&#xa0;or moderate in severity. COVID-19 (19.7%) and headache (12.7%) were the most common AEs. Three serious AEs, unrelated to remibrutinib, were reported. No deaths occurred during the treatment period. At week&#xa0;12, mean change from baseline in weekly Urticaria Activity Score (UAS7) and weekly Itch/Hives Severity Scores was − 18.1, − 8.0, and − 10.1, respectively; responses appeared to occur as early as week&#xa0;1 and appeared to be sustained until week&#xa0;52. Additionally, 53.6% of the patients had well-controlled disease (UAS7 ≤ 6) and 30.4% had complete&#xa0;absence of itch and hives (UAS7 = 0) at week&#xa0;52.</p> Conclusion <p>Remibrutinib showed a favorable safety profile and a meaningful improvement in CSU symptoms (itch and hives) at week&#xa0;12, with fast improvement as early as week&#xa0;1 that was sustained up to week&#xa0;52, supporting its potential as an effective oral BTK inhibitor for Japanese patients with CSU.</p> Trial Registration <p>Trial Registration: NCT05048342.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Remibrutinib Showed a Favorable Safety Profile and Sustained Efficacy in Japanese Patients with Chronic Spontaneous Urticaria Over 52 Weeks

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月19日

查看全文
  • Koremasa Hayama,
  • Yuko Chinuki,
  • Akiko Yagami,
  • Akihiro Kume,
  • Atsuya Morita,
  • Sakiko Miyazu,
  • Karine Lheritier,
  • Lukasz Jaskiewicz,
  • Sibylle Haemmerle,
  • Michihiro Hide

摘要

Introduction

Remibrutinib, an oral, highly selective, Bruton’s tyrosine kinase (BTK) inhibitor, has shown efficacy and favorable safety in pivotal global phase 3 studies in patients with chronic spontaneous urticaria (CSU). This 52-week safety study evaluated the effect of remibrutinib in Japanese patients with CSU.

Methods

BISCUIT, a phase 3 (NCT05048342), open-label, single-arm study, investigated the safety and efficacy of remibrutinib 25 mg twice-daily as an add-on medication in Japanese patients with CSU who remain symptomatic despite treatment with H1-antihistamines. The primary endpoint was the proportion of patients with ≥ 1 adverse events (AEs).

Results

Overall, 71 Japanese patients (mean age 43.5 years) had a median remibrutinib exposure of 52.1 weeks; 87.3% of patients reported ≥ 1 AE, and all events were mild or moderate in severity. COVID-19 (19.7%) and headache (12.7%) were the most common AEs. Three serious AEs, unrelated to remibrutinib, were reported. No deaths occurred during the treatment period. At week 12, mean change from baseline in weekly Urticaria Activity Score (UAS7) and weekly Itch/Hives Severity Scores was − 18.1, − 8.0, and − 10.1, respectively; responses appeared to occur as early as week 1 and appeared to be sustained until week 52. Additionally, 53.6% of the patients had well-controlled disease (UAS7 ≤ 6) and 30.4% had complete absence of itch and hives (UAS7 = 0) at week 52.

Conclusion

Remibrutinib showed a favorable safety profile and a meaningful improvement in CSU symptoms (itch and hives) at week 12, with fast improvement as early as week 1 that was sustained up to week 52, supporting its potential as an effective oral BTK inhibitor for Japanese patients with CSU.

Trial Registration

Trial Registration: NCT05048342.